Bridgene Biosciences

Developer of small-molecule drugs for the treatment of cancer

placeSunnyvale, California, United States calendar_todayFounded 2018 groups25 employees language bridgenebio.com

Registered entities

Social engagement

Social engagement: 5.1K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

10 investors on record; lead investors include Kaitai Capital Management, Lapam Capital, Deyi Capital, Junson Capital.

Investor typeCountShare
Venture capital550%
Private equity220%
Angel & family office110%
Other / undisclosed220%

Recent activity

5 Jun 2026
Event
BIO 2026
12 Mar 2026
Event
BIO-Europe Spring 2026
14 Jan 2026
Partnership
Lilly team through TuneLab
Coming soon